Tirzepatide PubMed research: what the peer-reviewed evidence says

Which trial results should carry most weight when you read PubMed?

The decision most people face when reading tirzepatide research is knowing which papers are worth treating as reliable. The SURMOUNT programme is the weight-management core: SURMOUNT-1 randomised 2,539 adults with obesity (without diabetes), comparing three doses of tirzepatide against placebo over 72 weeks. Average body-weight reduction at 15 mg was around 20–21%, with roughly 57% of participants at that dose losing at least 20% of their starting weight. These figures appear frequently in secondary sources; the primary record is on the SURMOUNT-1 paper in the New England Journal of Medicine, which is the source worth opening if you want the full methodology.

SURMOUNT-2 extended the work into adults with type 2 diabetes, finding similar dose-response patterns but somewhat smaller absolute weight reductions, consistent with the biology of insulin resistance. The SURPASS series, running in parallel, investigated tirzepatide's effect on HbA1c and cardiovascular markers in people with diabetes. Taken together, the programme involves well over 10,000 participants across both weight-management and diabetes trials. If a PubMed search returns a tirzepatide paper, it is worth checking which population was studied: results in people with type 2 diabetes do not map directly onto results in people without it.

The evidence base for tirzepatide's UK licence for weight management rests primarily on SURMOUNT-1 and SURMOUNT-2, which informed NICE's technology appraisal and the MHRA's licensing decision.

What the head-to-head evidence against semaglutide shows

Until 2025, most comparisons between tirzepatide and semaglutide were indirect, drawn from separate trials with different populations and follow-up periods. SURMOUNT-5 changed that. Published in the New England Journal of Medicine in 2025, the open-label trial randomised 751 adults with obesity but without diabetes to either tirzepatide or semaglutide 2.4 mg over 72 weeks. Tirzepatide produced greater average weight loss. NICE's committee, reviewing the evidence for TA1026, also noted that indirect comparisons favoured tirzepatide against semaglutide at the same follow-up point.

What SURMOUNT-5 did not cover is the new 7.2 mg semaglutide dose, the MHRA approved that in early 2026, after the trial was designed, so no published head-to-head exists at that dose yet. This is a genuine gap in the current published literature, and it matters if you are trying to compare the two medicines at their respective upper ends. The comparison between Mounjaro and other treatments is still evolving as newer data emerges.

It is also worth noting that trial populations are selected: SURMOUNT-5 excluded people with type 2 diabetes. Extrapolating results to people who do have diabetes requires care, and individual response to either medicine varies enough that population averages are a starting point, not a forecast.

How NICE and the MHRA used this evidence, and what that means for eligibility

NICE's appraisal of tirzepatide (TA1026, published December 2024, updated September 2025) drew directly on the SURMOUNT trial data to set the NHS eligibility criteria. For NHS access, adults generally need a BMI of at least 35 plus at least one qualifying weight-related condition, thresholds that the NICE committee calibrated against the trial's inclusion criteria. The phased NHS rollout means availability is expanding gradually, and not everyone who might benefit clinically meets the current access threshold.

For private treatment, the licensed eligibility is broader: adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, prediabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber still assesses the whole picture before approving anything; eligibility criteria from trials are not the same as a personal clinical decision. If you want to understand what the evidence means for your own situation, that is exactly the conversation a consultation is for.

The how tirzepatide is licensed page covers the MHRA's approved indications in more detail, while the Mounjaro overview explains how the medicine is supplied and what the treatment schedule looks like in practice.

What PubMed research does not settle, and who makes the actual decision

Clinical trials answer group-level questions. A 72-week trial tells you what happened, on average, to people who met the inclusion criteria and stayed on treatment. It does not tell you how your body will respond, how well you will tolerate the titration schedule, or whether a weight-related condition you have will interact with the medicine in ways the trial did not measure. That gap between published evidence and individual care is precisely where a prescriber works.

Research also does not settle questions about long-term outcomes beyond the trial window, or what happens after stopping treatment, areas where further studies are ongoing. The pancreatitis signal, for example, is real enough that in January 2026 the MHRA issued a formal Drug Safety Update highlighting it as a known, infrequent but potentially serious risk, something a prescriber weighs alongside your personal history. If you are exploring how dosing works in practice, you can read about tirzepatide 10, which is one of the maintenance doses used during the titration schedule, or look into tirzepatide 30, the higher-strength option that some people progress to over the course of treatment.

If you have spent time reading PubMed and want to discuss what you have found with a clinician, a consultation is the right next step. Our clinical team reviews each assessment personally. You can also read about weight-loss treatment options more broadly, or check the frequently asked questions if something specific is on your mind. Take your time with it. Check your eligibility when you are ready, there is no pressure to rush.